Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | GFER | P55789 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | IGLV6-57 | P01721 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | GPX4 | P36969 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9365623 | 0.92 | ALDH1A1 (0.52) | ALDH1A1CYP3A4GFERLMNATSHR | |
| SCHEMBL8391381 | 0.92 | ALDH1A1 (0.45) | ALDH1A1CYP3A4GFERLMNATSHR | |
| SCHEMBL30124196 | 0.92 | ALDH1A1 (0.45) | ALDH1A1CYP3A4GFERLMNATSHR | |
| Hydrochloric Acid SCHEMBL9437914 | 0.90 | ALDH1A1 (0.50) | ALDH1A1CYP3A4GFERLMNATSHR | |
| SCHEMBL21065775 | 0.90 | ALDH1A1 (0.44) | ALDH1A1CYP3A4GFERLMNATSHR | |
| Lithium Ion SCHEMBL19732619 | 0.90 | ALDH1A1 (0.44) | ALDH1A1CYP3A4GFERLMNATSHR | |
| SCHEMBL8391459 | 0.89 | ALDH1A1 (0.48) | ALDH1A1CYP3A4GFERLMNATSHR | |
| SCHEMBL11146469 | 0.89 | ALDH1A1 (0.50) | ALDH1A1CYP3A4GFERLMNATSHR | |
| SCHEMBL457496 | 0.88 | ALDH1A1 (0.61) | ALDH1A1CYP3A4GFERLMNATSHR | |
| SCHEMBL30565134 | 0.88 | ALDH1A1 (0.61) | ALDH1A1CYP3A4GFERLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3394056-B1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2021-04-14 | — | — | EP | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
| US-20130122050-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | DIAKINE THERAPEUTICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130122050-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | DIAKINE THERAPEUTICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8106031-B2 | Hydrolytically-resistant boron-containing therapeutics and methods of use | ANACOR PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20110052625-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | DIAKINE THERAPEUTICS, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110052625-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | DIAKINE THERAPEUTICS, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20090269313-A1 | ENCAPSULATION SYSTEM | DIAKINE THERAPEUTICS, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090269313-A1 | ENCAPSULATION SYSTEM | DIAKINE THERAPEUTICS, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-7517900-B2 | Pyrazole derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-14 | — | — | US | disclosed |
| WO-2005090291-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2005-09-29 | — | — | WO | disclosed |
| US-4918183-A | Monoazo dyes, process for their preparation, and the use thereof | CIBA-GEIGY CORPORATION (US) | 1990-04-17 | — | — | US | disclosed |
| US-4906740-A | Monoazo dyes containing as the azo component A phenylsulfonylphenyl radical | CIBA-GEIGY CORPORATION (US) | 1990-03-06 | — | — | US | disclosed |
| EP-0102325-B1 | MONOAZO DYESTUFFS, THEIR PREPARATION AND THEIR USE | CIBA-GEIGY AG (CH) | 1987-01-21 | — | — | EP | disclosed |
| US-4602084-A | Monoazo dyes containing a 4-substituted-2-azo-1,1'-diphenylsulfone component | CIBA-GEIGY CORPORATION (US) | 1986-07-22 | — | — | US | disclosed |
| EP-0101664-B1 | MONOAZO DYESTUFFS, THEIR PREPARATION AND THEIR USE | CIBA-GEIGY AG (CH) | 1986-06-04 | — | — | EP | disclosed |
| EP-0101408-B1 | MONOAZO DYESTUFFS, THEIR PREPARATION AND THEIR USE | CIBA-GEIGY AG (CH) | 1986-05-07 | — | — | EP | disclosed |
| EP-0102325-A1 | Monoazo dyestuffs, their preparation and their use | CIBA-GEIGY AG (CH) | 1984-03-07 | — | — | EP | disclosed |
| EP-0101664-A1 | Monoazo dyestuffs, their preparation and their use | CIBA-GEIGY AG (CH) | 1984-02-29 | — | — | EP | disclosed |
| EP-0101408-A1 | Monoazo dyestuffs, their preparation and their use | CIBA-GEIGY AG (CH) | 1984-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130122050-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | IAPP, LITAF, IGF2BP1 | ALDH1A1 3797/4885CYP3A4 4863/4885GFER 4795/4885 |
| US-20110052625-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | IAPP, LITAF, IGF2BP1 | ALDH1A1 3599/4885CYP3A4 4833/4885GFER 4753/4885 |
| US-20090269313-A1 | ENCAPSULATION SYSTEM | GPR119, IAPP, LIPA | ALDH1A1 2216/4885CYP3A4 4454/4885GFER 2290/4885 |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | ALDH1A1 2765/4885CYP3A4 4589/4885GFER 4595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.